Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.

The American journal of the medical sciences - 1 Apr 2007

Yoshimoto Akihiro, Inuzuka Kanako, Kita Toshiyuki, Kawashima Atsuhiro, Kasahara Kazuo

Abstract excerpt

Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, and it shows favorable antitumor activity against chemorefractory nonsmall cell lung cancer (NSCLC). However, patients with NSCLC have few treatment options available if they are refractory to gefitinib. We describe a 49-year-old patient with NSCLC who had a complete response to initial gefitinib that lasted for 12 months....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Gene Amplification

Share to Lung Neoplasms

Share to Quinazolines

Share to Treatment Outcome

Source

Identifiers

PMID: 17435415
DOI: 10.1097/MAJ.0b013e31803b8acb

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.PMID 17435415Read ↗

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.Semantic proximity Read ↗

[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].Semantic proximity Read ↗

Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.Semantic proximity Read ↗

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.Semantic proximity Read ↗

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.Semantic proximity Read ↗

Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.Semantic proximity Read ↗

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.Semantic proximity Read ↗

Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.Semantic proximity Read ↗

Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.Semantic proximity Read ↗

Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.Semantic proximity Read ↗

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.Semantic proximity Read ↗

[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.